Dimerix Ltd

DXB

Company Profile

  • Business description

    Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

  • Contact

    425 Smith Street
    FitzroyVIC3065
    AUS

    T: +61 1300813321

    https://www.dimerix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    9

Stocks News & Analysis

stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks

Is this the $80 billion elephant Warren Buffett has been waiting for?

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks

Tesla: Board announces new pay package for CEO Elon Musk

A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,028.80106.801.20%
CAC 407,650.1818.170.24%
DAX 4023,854.4696.770.41%
Dow JONES (US)44,173.6442.660.10%
FTSE 1009,152.7824.480.27%
HKSE24,873.28139.830.57%
NASDAQ21,053.58403.451.95%
Nikkei 22540,549.54258.840.64%
NZX 50 Index12,877.04193.001.52%
S&P 5006,329.9491.931.47%
S&P/ASX 2008,770.40106.701.23%
SSE Composite Index3,617.6034.290.96%

Market Movers